Pascal Richette

Sep 20, 2024 | fis.tu-dresden.de | Tim Jansen |Pascal Richette |Fernando Perez-Ruiz

Abstract Externe IDs PubMed 20401506 SchlagworteAllopurinol, Febuxostat, Gout, Urate-lowering therapy, Uricosuric, Xanthine-oxidase inhibitor

Aug 21, 2024 | jamanetwork.com | Pascal Richette |Nicola Dalbeth |Lisa K Stamp

Surrogate Markers and Clinical Outcomes Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Joshua D. Wallach, PhD, MS; Samuel Yoon, BS, BA; Harry Doernberg, MM; Laura R. Glick, MD; Oriana Ciani, PhD; Rod S. Taylor, PhD; Maryam Mooghali, MD; Reshma Ramachandran, MD, MHS, MPP; Joseph S. Ross, MD, MHS Surrogate Markers and Clinical Outcomes—Reply Joshua D. Wallach, PhD, MS; Reshma Ramachandran, MD, MPP, MHS; Joseph S.

Apr 25, 2024 | nature.com | Pascal Richette |Nicola Dalbeth

Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.

Jan 3, 2024 | acrjournals.onlinelibrary.wiley.com | Robin Christensen |Robin Christensen |Kristian Zobbe |Sabrina M Nielsen |Lisa K Stamp |Marius Henriksen | +9 more

Supporting Information Filename Description art42790-sup-0001-Disclosureform.pdfPDF document, 792.2 KB Disclosure Form